Evoke closes 2.2% below IPO on first day; Ophthotech gains 19.6%
This article was originally published in Scrip
Executive Summary
Evoke Pharma priced an initial public offering of 2.1m shares at $12 each to raise $25.2m, but the gastrointestinal disease specialist's stock closed down 2.2% at $11.74 per share at the end of its first trading day on 25 September while eye drug-focused Ophthotech's stock closed 19.6% above its $22 IPO value at $26.30.